Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00484679 · ClinicalTrials.gov registry record · Phase 2
Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00484679 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 18 participants.
The verdict
NCT00484679, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.
Interventions
- DRUG Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00484679
The ClinicalTrials.gov registry entry for NCT00484679 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triamcinolone Acetonide 10 mg/mL (Kenalog-10) is the first listed.
NCT00484679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00484679 about?
NCT00484679 is a clinical study titled "Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata". The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.
What is the current status of trial NCT00484679?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2007-05. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00484679?
The interventions under investigation include: Triamcinolone Acetonide 10 mg/mL (Kenalog-10) (DRUG).
Who is sponsoring clinical trial NCT00484679?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.